-
Mofokeng's first goal wins cup final for Orlando Pirates
-
Torres hat-trick helps Barca down Betis to extend Liga lead
-
Bielle-Biarrey strikes twice as Bordeaux win Champions Cup opener in S.Africa
-
Liverpool humbled again by Leeds fightback for 3-3 draw
-
'Democracy has crumbled!': Four arrested in UK Crown Jewels protest
-
Contenders plot path to 2026 World Cup glory as FIFA reveals tournament schedule
-
Inter thump Como to top Serie A ahead of Liverpool visit
-
Maresca fears Chelsea striker Delap faces fresh injury setback
-
Consistency the key to Man City title charge – Guardiola
-
Thauvin on target again as Lens remain top in France
-
Greyness and solitude: French ex-president describes prison stay
-
Frank relieved after Spurs ease pressure on under-fire boss
-
England kick off World Cup bid in Dallas as 2026 schedule confirmed
-
Milei welcomes Argentina's first F-16 fighter jets
-
No breakthrough at 'constructive' Ukraine-US talks
-
Bielle-Biarrey double helps Bordeaux-Begles open Champions Cup defence with Bulls win
-
Verstappen looking for a slice of luck to claim fifth title
-
Kane cameo hat-trick as Bayern blast past Stuttgart
-
King Kohli says 'free in mind' after stellar ODI show
-
Arsenal rocked by Aston Villa, Man City cut gap to two points
-
Crestfallen Hamilton hits new low with Q1 exit
-
Sleepless in Abu Dhabi - nervy times for Norris says Rosberg
-
Arsenal will bounce back from Villa blow: Arteta
-
UN Security Council delegation urges all sides to stick to Lebanon truce
-
Verstappen outguns McLarens to take key pole in Abu Dhabi
-
Syria's Kurds hail 'positive impact' of Turkey peace talks
-
Verstappen takes pole position for season-ending Abu Dhabi GP
-
Jaiswal hits ton as India thrash S. Africa to clinch ODI series
-
UK's Farage rallies in Scottish town hit by immigration protests
-
Saracens kick off European campaign by crushing Clermont
-
Arsenal rocked by Villa as Buendia ends leaders' unbeaten run
-
Venezuela's Machado vows to make Nobel Peace Prize ceremony
-
Kidnapping fears strain family bonds in Nigeria
-
'Chosen' Mbappe on way to making Real Madrid history like Ronaldo: Alonso
-
Russian strikes on Ukraine trigger heating, water cuts
-
Mediators Qatar, Egypt call for next steps in Gaza truce
-
Olympic favourite Malinin pulls off stunning GP Final win
-
Venezuela's Machado to receive peace prize in Oslo: Nobel Institute
-
Russell tops practice times to outpace title-chasing trio
-
India bowl out South Africa for 270 after De Kock ton
-
England staring down the barrel under Gabba lights as Australia dominate
-
Egyptian actor faces challenge in iconic role of singer Umm Kulthum
-
Chock and Bates win Grand Prix Final ice dance
-
Starvation fears as flood toll passes 900 in Indonesia
-
Four civilians, soldier killed in Afghan-Pakistan border clash
-
Milan-Cortina chief admits venue time pinch as Olympic torch relay begins
-
England make quick start after Australia take big lead at Gabba
-
Finally! India break toss jinx as Rahul gets lucky
-
Will EU give ground on 2035 combustion-engine ban?
-
England nemesis Starc stretches Australia lead in Gabba Ashes Test
| SCS | -0.56% | 16.14 | $ | |
| GSK | -0.33% | 48.41 | $ | |
| NGG | -0.66% | 75.41 | $ | |
| CMSD | -0.3% | 23.25 | $ | |
| BCC | -1.66% | 73.05 | $ | |
| RBGPF | 0% | 78.35 | $ | |
| BP | -3.91% | 35.83 | $ | |
| BTI | -1.81% | 57.01 | $ | |
| CMSC | -0.21% | 23.43 | $ | |
| AZN | 0.17% | 90.18 | $ | |
| BCE | 1.4% | 23.55 | $ | |
| VOD | -1.31% | 12.47 | $ | |
| RELX | -0.55% | 40.32 | $ | |
| RYCEF | -0.34% | 14.62 | $ | |
| RIO | -0.92% | 73.06 | $ | |
| JRI | 0.29% | 13.79 | $ |
Verseon Chooses DataKrypto's FHEnom for AI(TM) to Ensure Continuous Encryption of AI-Driven Medical Research and Clinical Trial Data
News Summary:
Verseon International Corporation's mission is to drive groundbreaking scientific advances and transform modern medicine through physics- and AI-driven drug design, development, and clinical trials.
Verseon utilizes AI to accelerate and enhance innovation by analyzing sensitive clinical trial and patient data. To maintain compliance and uphold strict data privacy standards, Verseon must ensure data is protected at all times.
DataKrypto's new FHEnom for AI™ combines its revolutionary fully homomorphic encryption (FHE) with Trusted Execution Environments (TEEs) to deliver unprecedented data security for proprietary datasets.
The unique capabilities of the DataKrypto solution safeguard against malicious activities, misuse, and adversarial manipulation, fostering trust and dependability in AI-generated outcomes.
News Summary:
Verseon International Corporation's mission is to drive groundbreaking scientific advances and transform modern medicine through physics- and AI-driven drug design, development, and clinical trials.
Verseon utilizes AI to accelerate and enhance innovation by analyzing sensitive clinical trial and patient data. To maintain compliance and uphold strict data privacy standards, Verseon must ensure data is protected at all times.
DataKrypto's new FHEnom for AI™ combines its revolutionary fully homomorphic encryption (FHE) with Trusted Execution Environments (TEEs) to deliver unprecedented data security for proprietary datasets.
The unique capabilities of the DataKrypto solution safeguard against malicious activities, misuse, and adversarial manipulation, fostering trust and dependability in AI-generated outcomes.
BURLINGAME, CA / ACCESS Newswire / October 1, 2025 / DataKrypto, the creator of the fastest fully homomorphic encryption (FHE) solutions on the market, announced today that Verseon, a drug development innovator, is deploying its cutting-edge FHEnom for AI to ensure the continuous security of AI datasets and proprietary models.
Verseon's team of scientists, biologists, and medical researchers works diligently to create medicines that improve the world's treatment of all major human diseases. AI plays a vital role in Verseon's drug development and clinical trials, and ensuring that highly sensitive data is always protected, throughout AI training and inference, is crucial for maintaining compliance with stringent data privacy regulations.

"DataKrypto's FHEnom for AI gives us a secure, continuously encrypted solution for our AI training, fine-tuning, and real-world usage," said David Kita, CSO of Verseon. "With implementation taking just hours, the solution combines security with convenience and speed, allowing us to focus on our core activities."
"Verseon's mission-critical drug discovery and development work is reliant on its ability to maintain continuous protection of its clinical trial data and proprietary AI models," said Ravi Srivatsav, CEO of DataKrypto. "FHEnom for AI fills the encryption gap by enabling AI training and processing without having to decrypt data, which potentially exposes it to malicious use. We are proud to provide the first solution that gives companies like Verseon confidence and peace of mind with their AI implementations, knowing that their data is always secure."
Building Trust in AI with DataKrypto
FHEnom for AI is an AI-compliant, zero-knowledge framework that safeguards both customized open-source AI models (adapted for specific enterprise needs) and proprietary models, while ensuring the privacy and protection of sensitive data. It defends against malicious activities, misuse, and adversarial manipulation, securing intellectual property and maintaining the confidentiality of critical datasets. DataKrypto's solution helps companies deploying AI overcome concerns about data privacy and model security.
For more information about FHEnom for AI, visit https://datakrypto.com/products/.
About Verseon
Verseon International Corporation (www.verseon.com) is transforming the delay, prevention, and treatment of disease. Using its Deep Quantum Modeling + AI platform, Verseon is rolling out a steady stream of life-changing medicines. Each of the company's drug programs features multiple novel candidates with unique therapeutic properties. Other current methods can find none of these candidates. Verseon's rapidly growing pipeline addresses major human diseases in the areas of cardiometabolic disorders and cancer. The company's supporters and advisors include multiple Nobel laureates, former heads of R&D at major pharmaceutical companies, and various key opinion leaders in the field of medicine.
About DataKrypto
DataKrypto reimagines AI security for the enterprise. By combining FHEnom™-the fastest, most scalable Fully Homomorphic Encryption technology available-with Trusted Execution Environments (TEEs), DataKrypto enables organizations to adopt, create, and use AI tools with unmatched security and performance. Every model, every dataset-always encrypted. Even the largest AI systems run securely, with performance intact. DataKrypto empowers organizations to embrace AI, ensuring protection at every step. Learn more at www.datakrypto.com.
Media Contact:
Liz Youngs
Trier and Company for DataKrypto
1-843-412-6327
[email protected]
SOURCE: DataKrypto
View the original press release on ACCESS Newswire
R.Garcia--AT